{"id":390045,"date":"2021-04-08T00:00:00","date_gmt":"2021-04-08T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0012-2020-biopharma-bladder-cancer-disease-landscape-and-forecast-g7-2020\/"},"modified":"2026-03-31T10:43:30","modified_gmt":"2026-03-31T10:43:30","slug":"dlsfon0012-2020-biopharma-bladder-cancer-disease-landscape-and-forecast-g7-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0012-2020-biopharma-bladder-cancer-disease-landscape-and-forecast-g7-2020\/","title":{"rendered":"Bladder Cancer | Disease Landscape and Forecast | G7 | 2020"},"content":{"rendered":"<p>The 2016\/17 FDA approvals of five immune checkpoint inhibitors for platinum-treated patients have significantly altered the treatment landscape for advanced bladder cancer, which has historically been dominated by chemotherapies. Keytruda (Merck) and Tecentriq (Roche \/ Genentech) have since been approved for previously untreated patients, with\u00a0Keytruda gaining quick FDA approval in the non-muscle-invasive, BCG-unresponsive population as immune checkpoint inhibitors have spread\u00a0across different stages of disease. Biomarker-driven treatments are becoming increasingly attractive,\u00a0highlighted by Balversa\u2019s FDA approval in April 2019. Furthermore, the entrance of Padcev in the third-line setting in the United States provides patients with an extra treatment option for metastatic disease. Given the intense Phase II\/III pipeline activity, we anticipate the approval of several new therapies for both muscle-invasive and non-muscle-invasive bladder cancer within the forecast period.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>What are the sizes of the clinically and commercially relevant drug-treatable bladder cancer populations, and how will drug-treatment rates change over time?<\/li>\n<li>How is bladder cancer currently treated, and what are the (dis)advantages of existing drugs? What is the expected market impact of recent approvals?<\/li>\n<li>Which of the emerging therapies seem most promising, and what sales\/uptake could they secure in the bladder cancer market?<\/li>\n<li>What are the drivers and constraints in the bladder cancer market, and how will the market evolve over the 10-year forecast period?<\/li>\n<\/ul>\n<p><strong>Geographies:<\/strong> United States, EU5, Japan.<\/p>\n<p><strong>Primary Research:<\/strong> 20 country-specific interviews with thought-leading urologists and medical oncologists. Supported by survey data collected for this and other DRG research.<\/p>\n<p><strong>Epidemiology:<\/strong> Diagnosed and recurrent incidence of bladder cancer by country, segmented by clinically and commercially relevant drug-treatable populations.<\/p>\n<p><strong>Forecast: <\/strong>Ten-year, annualized, drug-level sales and patient share of key bladder cancer therapies through 2028, segmented by brands \/ generics and epidemiological subpopulations.<\/p>\n<p><strong>Emerging Therapies: <\/strong>Phase III\/PR: 13 drugs; Phase II: 11 drugs; coverage of select preclinical and Phase I products.<\/p>\n<p><strong>Product Description<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution Enhancement<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast <\/em>will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.<\/p>\n","protected":false},"template":"","class_list":["post-390045","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-bladder-cancer","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390045","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390045\/revisions"}],"predecessor-version":[{"id":576414,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390045\/revisions\/576414"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390045"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}